Heparin-induced Thrombocytopenia (HIT) Market Size & Share, by Drug Type (Lepirudin, Danaparoid, Argatroban); Test Type (Enzyme Immunoassay, Serotonin Release Assay, Enzyme Linked Immunosorbent Assay, Heparin-induced Platelet Activation Test); End User (Hospitals, Diagnostic Centers, Specialized Clinics, Hospital Pharmacy, Homecare Setting, Mail Order Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5848
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Heparin-induced Thrombocytopenia Market size is expected to reach USD 63 Billion by the end of 2036, growing at a CAGR of 5% during the projected period i.e., between 2024-2036. In the year 2023, the industry size of heparin-induced thrombocytopenia was over USD 10 Billion. Heparin-induced thrombocytopenia may be a driving cause of horribleness and mortality in hospitalized patients, happening as an after-effect of life and limb-threatening thrombosis. In a least 5% of patients getting heparin, this condition is watched.There are signs of a diminish in the number of platelets by more than 50 % and encourage the arrangement of blood clots. Consequently, it is becoming profoundly vital to treat this condition, clearing the way for a have of treatment approaches. 

Heparin is widely used in acute coronary syndromes, atrial fibrillation, venous thromboembolism, dialysis, peripheral occlusive disease, and during extracorporeal circulation which increases the risk of heparin-induced thrombocytopenia and drives heparin-induced thrombocytopenia market.


Heparin-induced Thrombocytopenia (HIT) Market
Get more information on this report: Request Free Sample PDF

Heparin-induced Thrombocytopenia Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Research Activities and Investments - The expanding inquiries about exercises and subsidizing are anticipated to boost the worldwide heparin-induced thrombocytopenia market development amid the figure period. For example, in June 2023, Veralox Therapeutics, a clinical-stage biotechnology organization outlined a special sort of treatment focusing on the 12-lipoxygenase pathway to oversee a few of the treatment's impressively consistent and extreme immune-mediated clutters. Moreover, Veralox gotten $24 million in financing to advance VLX-1005 by means of a Stage 2a proof-of-concept examination evaluating its impact on heparin-induced thrombocytopenia, a life-threatening occasional condition initiated by an distorted safe reaction to heparin introduction. 
  • Presence of Advanced Diagnostic Tools - The key role in boosting the global market for heparin-induced thrombocytopenia is played by advanced diagnostic tools. Among the newer diagnostics tools that have transformed diagnosis of HIT are enzyme linked immunosorbate assays and particle gel immunoassay. These tests are highly sensitive and specific, making it easier for healthcare professionals to detect the presence of HIT antibodies in patients' blood. This enhanced accuracy ensures that individuals at risk of HIT are diagnosed promptly, enabling timely intervention and appropriate treatment.

Challenges

  • High Cost of Treatment - In view of the long duration of treatment with frequent doses over time, high costs for HIT therapy are expected to hamper global heparin-induced thrombocytopenia market. growth during the forecast period. For example, little data are available on the public comparison of the cost-effectiveness of these treatments despite the availability of significant non-heparin anticoagulants for the treatment of heparin-induced thrombocytopenia. The prolonged duration of therapy is a major reason for the slowdown in market growth over the forecast period, as treatment costs are high.
  • Side effects associated with the treatment are anticipated to hamper the market growth in the upcoming period.
  • Growing number of complications associated with treatment are set to hamper the heparin-induced thrombocytopenia market growth in the upcoming period.

Heparin-induced Thrombocytopenia (HIT) Market: Key Insights

Base Year

2023

Forecast Year

2024 – 2036

CAGR

~5%

Base Year Market Size

~USD 10 billion

Forecast Year Market Size

~USD 63 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Heparin-induced Thrombocytopenia Segmentation

Drug Type (Lepirudin, Danaparoid, Argatroban)

Based on drug type, argatroban segment in the heparin-induced thrombocytopenia (HIT) market is set to hold the largest revenue share of 50% by the end of 2036. Due to the new product introductions in this segment, the argatroban treatment is expected to dominate the global market. For occurrence, in April 2023 Endo International plc's Par Sterile Products trade began dispatching argatroban infusion to healthcare providers by means of Premier's Chief ProRx private-label plan, a guarantor save for clinics and health frameworks. Argatroban is on the FDA's elementary drugs checklist and has experienced discontinuous save issues in the market. 

End User (Hospitals, Diagnostic Centers, Specialized Clinics, Hospital Pharmacy, Homecare Setting, Mail Order Pharmacy)

In terms of end-user, the hospital segment is anticipated to hold 40% share of the global heparin-induced thrombocytopenia market by 2036. In order to provide special care for patients with HIT, hospitals and healthcare centers are well equipped. HIT is a complex condition that requires precise diagnosis, constant monitoring, and prompt treatment. In order to provide the level of care often required by HIT patients, these healthcare facilities have the necessary infrastructure, equipment, and experienced healthcare professionals.

Our in-depth analysis of the global market includes the following segments:

     Drug Type

  • Lepirudin
  • Danaparoid
  • Argatroban

     Test Type

  • Enzyme Immunoassay
  •  Serotonin Release Assay
  • Enzyme Linked Immunosorbent Assay
  •  Heparin-induced Platelet Activation Test

     End User

  • Hospitals
  • Diagnostic Centers
  • Specialized Clinics
  •  Hospital Pharmacy
  •  Homecare Setting
  • Mail Order Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Heparin-induced Thrombocytopenia Industry - Regional Synopsis

North American Market Forecasts

The heparin-induced thrombocytopenia (HIT) Market in the North America region is anticipated to dominate the revenue, by registering growth of 35% by the end of 2036. Regional market growth is expected to be supported by an increased use of heparin in North America for the treatment of different disorders. Heparin is usually used for hemodialysis and the growing number of patients who are currently receiving dialysis will contribute to regional market growth. For instance, in February 2022, around 570,000 Americans receive dialysis, which indicates a notable heparin usage and its adverse drug reaction, Heparin-induced thrombocytopenia. In addition, regional market growth in the forecast period will be stimulated by recent product introductions on the market. For example, Gland Pharma Ltd., together with its associates MAIA Pharmaceuticals Inc. and Athenex Pharmaceutical Division, launched a ready to use formulation of Bivalirudin in the United States in June 2020. This was the first on-frozen ready-to-use bivalirudin 505b (2) NDA authorized by the U.S.

European Market Forecasts

The heparin-induced thrombocytopenia market in the Europe region is set to hold a substantial revenue share during the projected period. Continuous research and development in the field are leading to the introduction of novel therapies with enhanced efficacy and reduced side effects. This innovation is anticipated to attract new players and investments further propelling the heparin-induced thrombocytopenia market. expansion in the region. Furthermore, government initiatives and favorable reimbursement policies for effective HIT treatments can incentivize market growth and accessibility.

Research Nester
Heparin Induced Thrombocytopenia Treatment Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Heparin-induced Thrombocytopenia Landscape

top-features-companies
    • Endo International plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PlateletBio
    • AUROMEDICS PHARMA LLC
    • Fresenius Kabi USA
    • Pfizer Inc
    • Caplin Steriles Ltd
    • Hikma Pharmaceuticals PLC
    • NOVARTIS AG
    • Eagle Pharmaceutical Inc
    • WEST WARD INC
    • DAIICHI SANKYO COMPANY LIMITED
    • Mitsubishi Tanabe Pharma

In-the-news

In The News

  • Par Sterile Products, a subsidiary of Endo International plc, began to dispatch argatroban to healthcare providers via the Premier ProRx private label programme, an insured reserve for hospitals and health systems.
  • Platelet Bio, a biotechnology company dedicated to the discovery and development of an innovative platform for allogeneic cell therapy based on platelet biology, successfully raised $75.5 million in Series B funding in November 2021. Contributions from new investors, SymBiosis, K2 HealthVentures and Oxford Finance were also part of this funding round together with the ongoing support provided by existing investors. The company intends to use the proceeds of this financing, which represents groundbreaking treatment for immune thrombocytopenia, an autoimmunity disease, in order to advance preclinical development of its flagship program on plateletslike cells. In addition, Platelet Bio intends to further develop its innovative engineered PLC platform and enhance its own manufacturing capabilities.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5848
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of heparin-induced thrombocytopenia and increasing research and development activities are some of the major factors anticipated to drive the growth of the heparin-induced thrombocytopenia treatment market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Pfizer Inc, Caplin Steriles Ltd, Hikma Pharmaceuticals PLC, NOVARTIS AG, Eagle Pharmaceutical Inc, WEST WARD INC, and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Heparin Induced Thrombocytopenia Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying